• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Active Filters1
31 results

LAG-3 ANTAGONIST THERAPY FOR HEPATOCELLULAR CARCINOMA

Docket 18/43,562, U.S. Patent Application (Feb. 28, 2023)

cite Cite Docket
Analyze

LWRTEI09XBLUEX6

Document LAG-3 ANTAGONIST THERAPY FOR HEPATOCELLULAR CARCINOMA, 18/43,562, No. LWRTEI09XBLUEX6 (U.S. Pat. App. May. 30, 2024)

cite Cite Document
Analyze

LWRTEI0BXBLUEX6

Document LAG-3 ANTAGONIST THERAPY FOR HEPATOCELLULAR CARCINOMA, 18/43,562, No. LWRTEI0BXBLUEX6 (U.S. Pat. App. May. 30, 2024)

cite Cite Document
Analyze

LWRTEI0DXBLUEX6

Document LAG-3 ANTAGONIST THERAPY FOR HEPATOCELLULAR CARCINOMA, 18/43,562, No. LWRTEI0DXBLUEX6 (U.S. Pat. App. May. 30, 2024)

cite Cite Document
Analyze

Notice of Designated Office (DO) / Elected Office (EO) Acceptance Mailed

Document LAG-3 ANTAGONIST THERAPY FOR HEPATOCELLULAR CARCINOMA, 18/43,562, No. LWRTEI0AXBLUEX6 (U.S. Pat. App. May. 30, 2024)
United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS Alexandria, Virginia 22313-1450 ov www.uspto.gi 18/043,562 Shivani SRIVASTAVA 3338.2240002 115018 Sterne, Kessler, Goldstein & Fox P.L.L.C. BMS/Scripps 1101 K Steet, NW 10th Floor Washington, DC 20005 Date Mailed: 05/30/2024
The applicant is hereby advised that the United States Patent and TrademarkOffice, in its capacity as a Designated / Elected Office (37 CFR 1.495), has ACCEPTED the aboveidentified international application for national patentability examination in the United States Patent and TrademarkOffice.
A Filing Receipt will be issued for the present application in due course.
Basic National Feesfiled on 02/28/2023 FORM PCT/DO/EO/903 (371 Acceptance Notice)
Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)
cite Cite Document
Analyze

LLEBJZICXBLUEX4

Document LAG-3 ANTAGONIST THERAPY FOR HEPATOCELLULAR CARCINOMA, 18/43,562, No. LLEBJZICXBLUEX4 (U.S. Pat. App. Aug. 16, 2023)

cite Cite Document
Analyze

Preliminary Amendment

Document LAG-3 ANTAGONIST THERAPY FOR HEPATOCELLULAR CARCINOMA, 18/43,562, No. LLEBJZHZXBLUEX4 (U.S. Pat. App. Aug. 16, 2023)
Inventors: SRIVASTAVAef al.
Confirmation No.: 2437 Applicant: Bristol-Myers Squibb Company Art Unit: 1647 Application No.: 18/043,562 Filing Date: February 28, 2023 Examiner: 7o Be Assigned Atty.
If any additional fees are due other than those included with this response, the Office is authorized to charge such fees to Deposit Account No. 19-0036.
Amendments to the Claims begin on page 2 of this paper.
Remarksbegin on page8 ofthis paper.
cite Cite Document
Analyze

LLEBJZHLXBLUEX4

Document LAG-3 ANTAGONIST THERAPY FOR HEPATOCELLULAR CARCINOMA, 18/43,562, No. LLEBJZHLXBLUEX4 (U.S. Pat. App. Aug. 16, 2023)

cite Cite Document
Analyze
1 2 3 >>